| pubmed-article:9875375 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0206558 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0070895 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:9875375 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9875375 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9875375 | pubmed:dateCreated | 1999-2-11 | lld:pubmed |
| pubmed-article:9875375 | pubmed:abstractText | In a previous study, we reported that 1-O-octadecyl-sn-glycero-3-foscarnet (ODG-PFA) was 40 to 93 times more potent than free foscarnet (PFA) in human cytomegalovirus (HCMV)-, herpes simplex virus type 1 (HSV-1)- and human immunodeficiency virus type 1 (HIV-1)-infected cells. To evaluate the effect of substituting a 1-S-alkyl thioether for a 1-O-alkyl ether, we synthesized a series of PFA conjugates of 1-S-alkyl-sn-thioglycerols with varied 1-S-alkyl chain lengths. To establish structure-activity relationships we measured the in vitro antiviral activity of liposomal formulations of the drugs in cells infected with HCMV, HSV-1 or HIV-1. The optimum 1-S-alkyl chain length in the series was 16 to 18 carbon atoms. We compared the antiviral activity of 16- and 18-carbon alkyl thioglycerol versus alkylglycerol prodrugs and did not observe any significant differences in their antiviral activities. The series' most active member, 1-S-octadecyl-sn-glycero-3-foscarnet (ODSG-PFA) was 56-, eight- and 45-fold more active than PFA in HCMV-, HSV-1- and HIV-1-infected cells in vitro. The oral absorption of PFA and 1-S-octadecyl-sn-thioglycero-3-PFA was compared in mice by measuring plasma levels of 14C after oral administration of radiolabelled compounds. The peak plasma level of 14C was sevenfold higher following administration of [14C]ODSG-PFA than following an equimolar dose of [14C]PFA. Area-under-the-curve was 23-fold greater for ODSG-PFA than for PFA. Like previously reported alkyloxyether-lipid PFA conjugates, alkylthioether conjugates provided enhanced antiviral activity and oral bioavailability. However, S-ether conjugates may be metabolized differently than O-ether conjugates. More detailed in vivo pharmacokinetic evaluation of the alkyl-thioether-PFA conjugates is required. | lld:pubmed |
| pubmed-article:9875375 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9875375 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9875375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9875375 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9875375 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9875375 | pubmed:issn | 0956-3202 | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:HostetlerK... | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:RichmanD DDD | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:WrightK NKN | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:GardnerM FMF | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:JANYPP | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:AldernK AKA | lld:pubmed |
| pubmed-article:9875375 | pubmed:author | pubmed-author:BeadleJ RJR | lld:pubmed |
| pubmed-article:9875375 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9875375 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9875375 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9875375 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9875375 | pubmed:pagination | 33-40 | lld:pubmed |
| pubmed-article:9875375 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:meshHeading | pubmed-meshheading:9875375-... | lld:pubmed |
| pubmed-article:9875375 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9875375 | pubmed:articleTitle | Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. | lld:pubmed |
| pubmed-article:9875375 | pubmed:affiliation | Department of Medicine, University of California, San Diego, La Jolla 92093-0676, USA. | lld:pubmed |
| pubmed-article:9875375 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9875375 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9875375 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9875375 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9875375 | lld:pubmed |
